Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has shared an update.
Zydus Lifesciences Limited has received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg, used for treating irritable bowel syndrome with diarrhea in adults. This approval grants Zydus 180 days of shared generic drug exclusivity, potentially impacting its market positioning positively, as the tablets had significant annual sales in the U.S. The approval marks another milestone for Zydus, which has accumulated 419 approvals and filed 483 ANDAs since 2003.
More about Zydus Lifesciences Limited
Zydus Lifesciences Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of pharmaceutical products. The company is involved in producing generic drugs and has a significant presence in the global market, particularly in the United States.
YTD Price Performance: -9.36%
Average Trading Volume: 45,891
Current Market Cap: 888.1B INR
See more insights into ZYDUSLIFE stock on TipRanks’ Stock Analysis page.